Business Wire

KROLL-ONTRACK

3.11.2016 11:13:33 CET | Business Wire | Press release

Share
Kroll Ontrack Launches Second Annual New Frontiers in Ediscovery Report

Kroll Ontrack , the leading global provider of ediscovery technologies and services to companies involved in litigation and investigations, today announced the launch of the second edition of its annual New Frontiers in Ediscovery Report.

The report highlights the continued and rapid international expansion in the use of ediscovery techniques and technologies by law firms and their clients as well as ongoing progress made in the capabilities of ediscovery itself and its inclusion in an ever expanding range of business processes.

Tim Phillips, Managing Director of Kroll Ontrack International Legal Technologies , said: “The use of ediscovery in litigation and regulatory compliance shows no signs of slowing down and is increasingly being adopted within general business itself. There is growing interest in technologies such as Predictive Coding and mobile ediscovery solutions used onsite as companies seek to reduce the cost of litigation and the risks associated with transferring data across borders. Countries in Europe that were traditionally hesitant about adopting ediscovery, notably Spain, Italy and those in Scandinavia, are now seeing the benefits of using sophisticated legal technologies such as predictive coding.

“There is also a marked trend by corporates all over the world to use ediscovery to proactively pre-empt problems, whether that means investigating third party supplier behaviour or analysing potential instances of bribery and corruption. More and more we are seeing ediscovery being used to anticipate problems before they occur, rather than reacting to them when they are already a serious - and potentially damaging issue - to address.

“Another noticeable development in this year’s report is the gap between the adoption of ediscovery in Western economies and those in the East, including China, Japan, Singapore and Hong Kong. This gap is shrinking quickly along with the emergence of new legislation and regulation relating to compliance and competition including the Counter-Terrorism Law of the People’s Republic of China. As the global leader in ediscovery, we believe it is important for us to continue monitoring these changes and ensuring organisations and their law firms are kept up to speed with developments.”

The new report outlines what’s happening with ediscovery and looks at the impact of changing data privacy regimes in different regions around the world, in the wake of seismic shifts caused by the cancellation of the US EU Safe Harbor, the emergence of the General Data Protection Regulation and Brexit in Europe. It also tracks developments in Digital Forensics behind the Lab Door; ediscovery technology and how organisations are using ediscovery to avoid corporate scandals. It includes valuable insights into how Kroll Ontrack works with Kroll, the global leader in risk mitigation, compliance, investigations, security, and incident response solutions, in complex, cross-border multidisciplinary investigations involving multiple jurisdictions and unique global challenges.

For more information on Kroll Ontrack and its products and services, visit www.ediscovery.com/uk

To download a copy of the Kroll Ontrack New Frontiers in Ediscovery Report, visit: http://www.ediscovery.com/uk/new-frontiers-in-ediscovery/

About Kroll Ontrack LLC

Kroll Ontrack provides technology-driven services and software to help legal, corporate and government entities as well as consumers manage, recover, search, analyse, and produce data efficiently and cost-effectively. In addition to its award-winning suite of software, Kroll Ontrack provides data recovery, data destruction, electronic discovery and document review services. For more information about Kroll Ontrack and its offerings please visit: http://www.ediscovery.com/uk and follow @KrollOntrackUK on Twitter.

Contact:

Citigate Dewe Rogerson
Charlotte Pascal/Judith Massey/Emma Castle
Tel: +44 20 7282 1021 / 2987 / 2993
Email: charlotte.pascal@citigate.co.uk / judith.massey@citigatedr.co.uk / emma.castle@citigatedr.co.uk

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye